article thumbnail

Amid Biden admin's drug-pricing push, Big Pharma kicks off 2024 with hundreds of price hikes: report

Fierce Pharma

While public and political scrutiny around drug pricing has reached a fever pitch in the wake of 2022’s Inflation Reduction Act (IRA), that hasn’t stopped pharma majors from ringing in 2024 with th | While public and political scrutiny around drug pricing has reached a fever pitch in the wake of 2022’s Inflation Reduction Act (IRA), that hasn’t stopped (..)

Pharma 347
article thumbnail

WuXi Biologics stays the course with positive 2024 outlook as national security crackdown threatens business in US

Fierce Pharma

WuXi Biologics stays the course with positive 2024 outlook as national security crackdown threatens business in US fkansteiner Wed, 03/27/2024 - 13:12

141
141
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2024 forecast: M&A saw an uptick in 2023. Analysts expect the trend to continue

Fierce Pharma

And it is with cautious optimism that industry watchers see the trend continuing in 2024. . | Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.

Biopharma 346
article thumbnail

‘The Top Line’: The most anticipated drug launches of 2024

Fierce Pharma

This week on “The Top Line,” we explore the most anticipated drug launches of 2024. This week on “The Top Line,” we explore the most anticipated drug launches of 2024.

Pharma 177
article thumbnail

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Fierce Pharma

In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said. Morgan Healthcare Conference. |

article thumbnail

Sanofi expects RSV antibody to ?breach blockbuster status in 2024, even as supply hitch drags on

Fierce Pharma

On both fronts, Sanofi expects to see dividends in 2024. . | As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial respiratory launch with partner AstraZeneca.

265
265
article thumbnail

2024 forecast: As CDMOs come off pandemic's highs and lows, employment and funding hitches persist

Fierce Pharma

In 2024, CDMOs can advance their priorities on three fronts, a group of experts said during a recent Evaluate webinar on the state of the industry. Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields.

Biopharma 276